28.03.2024 12:33:56
|
Gilead, Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program XTX301
(RTTNews) - Gilead Sciences, Inc. (GILD) and Xilio Therapeutics, Inc. (XLO) announced an exclusive license agreement on Thursday to collaborate on Xilio's Phase 1 tumor-activated IL-12 program, XTX301.
Under this agreement, Xilio will be granted $43.5 million in upfront payments, comprising a $30 million cash payment and an initial equity investment of $13.5 million by Gilead in Xilio common stock at a premium.
Xilio stands to earn up to $604 million in additional contingent payments, which involve further equity investments by Gilead, a transition fee, and specific development, regulatory, and sales-based milestones.
Xilio will be responsible for overseeing the clinical development of XTX301 in the existing Phase 1 clinical trial through dose expansion.
Upon submission of a defined clinical data package for XTX301 by Xilio, Gilead will have the option to take over the development and commercialization of XTX301, subject to the terms of the agreement and a $75 million payment by Gilead.
Preceding the potential transition fee, Xilio stands to receive further equity investments of up to $29 million and a development milestone payment.
This transaction is projected to decrease Gilead's GAAP and non-GAAP 2024 earnings per share by around $0.03 - $0.04.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Gilead Sciences Inc.mehr Nachrichten
28.02.25 |
NASDAQ Composite Index-Papier Gilead Sciences-Aktie: So viel hätten Anleger an einem Gilead Sciences-Investment von vor 5 Jahren verdient (finanzen.at) | |
21.02.25 |
NASDAQ Composite Index-Papier Gilead Sciences-Aktie: So viel hätten Anleger an einem Gilead Sciences-Investment von vor 3 Jahren verdient (finanzen.at) | |
20.02.25 |
Börse New York: NASDAQ 100 schlussendlich in Rot (finanzen.at) | |
20.02.25 |
Handel in New York: So entwickelt sich der NASDAQ 100 am Mittag (finanzen.at) | |
12.02.25 |
NASDAQ Composite aktuell: NASDAQ Composite zum Ende des Mittwochshandels mit Zuschlägen (finanzen.at) | |
12.02.25 |
NASDAQ 100 aktuell: NASDAQ 100 liegt schlussendlich im Plus (finanzen.at) | |
12.02.25 |
Angespannte Stimmung in New York: S&P 500 zum Handelsende schwächer (finanzen.at) | |
12.02.25 |
Börse New York: Das macht der NASDAQ Composite nachmittags (finanzen.at) |
Analysen zu Gilead Sciences Inc.mehr Analysen
Aktien in diesem Artikel
Gilead Sciences Inc. | 108,04 | 0,32% |
|
Xilio Therapeutics Inc Registered Shs | 0,91 | 1,56% |
|